| Chapter title |
Current medical treatment of glioblastoma.
|
|---|---|
| Chapter number | 7 |
| Book title |
Current Understanding and Treatment of Gliomas
|
| Published in |
Cancer treatment and research, December 2014
|
| DOI | 10.1007/978-3-319-12048-5_7 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-912047-8, 978-3-31-912048-5
|
| Authors |
Venur VA, Peereboom DM, Ahluwalia MS, Vyshak Alva Venur, David M. Peereboom, Manmeet S. Ahluwalia, Venur, Vyshak Alva, Peereboom, David M., Ahluwalia, Manmeet S. |
| Abstract |
Glioblastoma is the most common adult malignant primary brain tumor. Despite the advances in therapeutic options, survival of patients with glioblastoma remains dismal at 15-18 months. Current standard of care for newly diagnosed glioblastoma is maximal possible safe resection consistent with the preservation of neurologic function followed by concurrent temozolomide with radiation and adjuvant. Treatment options at recurrence include surgical resection with or without the placement of carmustine wafers, re-irradiation and chemotherapeutics such as nitrosoureas (lomustine, carmustine) or bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF). |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 2% |
| Unknown | 61 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 18% |
| Researcher | 11 | 18% |
| Student > Bachelor | 8 | 13% |
| Student > Doctoral Student | 6 | 10% |
| Student > Master | 3 | 5% |
| Other | 8 | 13% |
| Unknown | 15 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 34% |
| Biochemistry, Genetics and Molecular Biology | 9 | 15% |
| Neuroscience | 4 | 6% |
| Agricultural and Biological Sciences | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 18 | 29% |